Clinical Focus ›› 2023, Vol. 38 ›› Issue (11): 996-1001.doi: 10.3969/j.issn.1004-583X.2023.11.006
Previous Articles Next Articles
Shi Peihua1,2, Lin Yanlin2, Bi Lifang2()
Received:
2023-10-07
Online:
2023-11-20
Published:
2024-01-17
Contact:
Bi Lifang
E-mail:geshengyouyang2010@163.com
CLC Number:
Shi Peihua, Lin Yanlin, Bi Lifang. Study on the correlation of NLR, PLR and MLR with type 2 diabetes mellitus complicated with coronary heart disease[J]. Clinical Focus, 2023, 38(11): 996-1001.
Add to citation manager EndNote|Ris|BibTeX
URL: https://huicui.hebmu.edu.cn/EN/10.3969/j.issn.1004-583X.2023.11.006
指标 | 单纯T2DM组( | T2DM合并CHD组( | χ2/ | |
---|---|---|---|---|
男性[例(%)] | 49(21.2) | 182(78.8) | 18.760 | <0.01 |
年龄(岁) | 60.79±8.17 | 65.35±8.60 | 5.658 | <0.01 |
SBP(mmHg) | 142.67±18.74 | 145.52±22.03 | 1.511 | 0.132 |
DBP(mmHg) | 82.31±11.67 | 83.67±12.52 | 1.165 | 0.245 |
BMI[kg/m2] | 24.56(23.37, 26.57) | 25.30(23.85, 26.67) | 1.541 | 0.123 |
TC(mmol/L) | 4.82±1.09 | 4.97±1.13 | 1.423 | 0.155 |
TG(mmol/L) | 1.52(0.96, 2.31) | 1.48(1.00, 2.17) | 0.244 | 0.807 |
HDL-C(mmol/L) | 1.15(0.98, 1.32) | 1.13(0.92, 1.30) | 1.448 | 0.148 |
LDL-C(mmol/L) | 2.84(2.24, 3.38) | 2.99(2.36, 3.70) | 1.997 | 0.046 |
LDL-C/HDL-C | 2.40(1.99, 3.10) | 2.72(2.12, 3.45) | 2.929 | 0.003 |
FBG(mmol/L) | 7.46(5.81, 9.25) | 7.00(5.83, 9.38) | 0.787 | 0.431 |
HbA1c(%) | 6.80(6.30, 7.70) | 7.30(6.60, 8.38) | 3.618 | <0.01 |
BUN(mmol/L) | 5.90(5.00, 6.80) | 6.20(5.13, 7.40) | 2.185 | 0.029 |
Cr(μmol/L) | 58.00(49.25, 65.00) | 64.00(55.00, 77.00) | 4.799 | <0.01 |
UA(μmol/L) | 328.00(274.25, 389.00) | 331.00(284.00, 399.00) | 1.082 | 0.279 |
CysC(mg/L) | 0.88(0.80, 0.98) | 0.94(0.86, 1.05) | 4.236 | <0.01 |
NLR | 1.57(1.17, 1.93) | 2.08(1.52, 2.77) | 6.550 | <0.01 |
PLR | 101.94(84.15, 130.24) | 114.34(92.46, 142.73) | 3.571 | <0.01 |
MLR | 0.17(0.13, 0.21) | 0.22(0.17, 0.28) | 6.711 | <0.01 |
Tab. 1 Comparison of general data, biochemical indexes, NLR, PLR, MLR between the two groups
指标 | 单纯T2DM组( | T2DM合并CHD组( | χ2/ | |
---|---|---|---|---|
男性[例(%)] | 49(21.2) | 182(78.8) | 18.760 | <0.01 |
年龄(岁) | 60.79±8.17 | 65.35±8.60 | 5.658 | <0.01 |
SBP(mmHg) | 142.67±18.74 | 145.52±22.03 | 1.511 | 0.132 |
DBP(mmHg) | 82.31±11.67 | 83.67±12.52 | 1.165 | 0.245 |
BMI[kg/m2] | 24.56(23.37, 26.57) | 25.30(23.85, 26.67) | 1.541 | 0.123 |
TC(mmol/L) | 4.82±1.09 | 4.97±1.13 | 1.423 | 0.155 |
TG(mmol/L) | 1.52(0.96, 2.31) | 1.48(1.00, 2.17) | 0.244 | 0.807 |
HDL-C(mmol/L) | 1.15(0.98, 1.32) | 1.13(0.92, 1.30) | 1.448 | 0.148 |
LDL-C(mmol/L) | 2.84(2.24, 3.38) | 2.99(2.36, 3.70) | 1.997 | 0.046 |
LDL-C/HDL-C | 2.40(1.99, 3.10) | 2.72(2.12, 3.45) | 2.929 | 0.003 |
FBG(mmol/L) | 7.46(5.81, 9.25) | 7.00(5.83, 9.38) | 0.787 | 0.431 |
HbA1c(%) | 6.80(6.30, 7.70) | 7.30(6.60, 8.38) | 3.618 | <0.01 |
BUN(mmol/L) | 5.90(5.00, 6.80) | 6.20(5.13, 7.40) | 2.185 | 0.029 |
Cr(μmol/L) | 58.00(49.25, 65.00) | 64.00(55.00, 77.00) | 4.799 | <0.01 |
UA(μmol/L) | 328.00(274.25, 389.00) | 331.00(284.00, 399.00) | 1.082 | 0.279 |
CysC(mg/L) | 0.88(0.80, 0.98) | 0.94(0.86, 1.05) | 4.236 | <0.01 |
NLR | 1.57(1.17, 1.93) | 2.08(1.52, 2.77) | 6.550 | <0.01 |
PLR | 101.94(84.15, 130.24) | 114.34(92.46, 142.73) | 3.571 | <0.01 |
MLR | 0.17(0.13, 0.21) | 0.22(0.17, 0.28) | 6.711 | <0.01 |
指标 | 低危亚组( | 中危亚组( | 高危亚组( |
---|---|---|---|
男性[例(%)] | 63(41.7) | 51(52.6) | 68(63.0)* |
年龄(岁) | 65(61.00, 69.00) | 65(60.00, 69.50) | 68(61.00, 75.00)*# |
SBP(mmHg) | 146.93±18.94 | 147.94±24.97 | 141.42±22.83 |
DBP(mmHg) | 85.17±12.38 | 84.91±13.53 | 80.49±11.23*# |
BMI(kg/m2) | 25.03±2.74 | 25.27±1.72 | 25.76±1.96* |
TC(mmol/L) | 4.69(3.88,, 5.60) | 4.86(4.32, 5.64) | 5.03(4.47, 5.82)* |
TG(mmol/L) | 1.61(1.02, 2.22) | 1.48(1.07, 2.25) | 1.43(1.00, 2.02) |
HDL-C(mmol/L) | 1.11(0.91, 1.29) | 1.14(0.98, 1.29) | 1.14(0.90, 1.34) |
LDL-C(mmol/L) | 2.77(2.08, 3.58) | 2.96(2.44, 3.71) | 3.19(2.63, 3.80)* |
LDL-C/HDL-C | 2.56(2.01, 3.38) | 2.64(2.06, 3.45) | 2.88(2.32, 3.76)* |
FBG(mmol/L) | 7.08(5.97, 9.23) | 6.46(5.54, 8.14) | 7.50(5.70, 10.16)# |
HbA1c(%) | 7.30(6.70, 8.00) | 7.30(6.45, 8.50) | 7.40(6.53, 8.50) |
BUN(mmol/L) | 5.90(5.05, 7.10) | 6.30(5.00, 7.35) | 6.60(5.30, 8.10) |
Cr(μmol/L) | 59.00(51.00, 68.00) | 67.00(58.00, 79.00)* | 69.00(57.00, 86.00)* |
UA(μmol/L) | 316.50(275.00, 376.00) | 335.00(300.50, 398.50) | 349.00(297.50, 414.00)* |
CysC(mg/L) | 0.89(0.81, 1.01) | 0.94(0.86, 1.04) | 0.99(0.93, 1.14)*# |
NLR | 1.73(1.34, 2.38) | 1.81(1.48, 2.72) | 2.70(2.12, 3.72)*# |
PLR | 103.21(83.14, 124.78) | 111.22(88.52, 144.68) | 136.14(109.18, 168.27)*# |
MLR | 0.19(0.14, 0.24) | 0.20(0.16, 0.29) | 0.27(0.22, 0.34)*# |
Tab. 2 Comparison of general data, biochemical indexes, NLR, PLR, MLR between groups
指标 | 低危亚组( | 中危亚组( | 高危亚组( |
---|---|---|---|
男性[例(%)] | 63(41.7) | 51(52.6) | 68(63.0)* |
年龄(岁) | 65(61.00, 69.00) | 65(60.00, 69.50) | 68(61.00, 75.00)*# |
SBP(mmHg) | 146.93±18.94 | 147.94±24.97 | 141.42±22.83 |
DBP(mmHg) | 85.17±12.38 | 84.91±13.53 | 80.49±11.23*# |
BMI(kg/m2) | 25.03±2.74 | 25.27±1.72 | 25.76±1.96* |
TC(mmol/L) | 4.69(3.88,, 5.60) | 4.86(4.32, 5.64) | 5.03(4.47, 5.82)* |
TG(mmol/L) | 1.61(1.02, 2.22) | 1.48(1.07, 2.25) | 1.43(1.00, 2.02) |
HDL-C(mmol/L) | 1.11(0.91, 1.29) | 1.14(0.98, 1.29) | 1.14(0.90, 1.34) |
LDL-C(mmol/L) | 2.77(2.08, 3.58) | 2.96(2.44, 3.71) | 3.19(2.63, 3.80)* |
LDL-C/HDL-C | 2.56(2.01, 3.38) | 2.64(2.06, 3.45) | 2.88(2.32, 3.76)* |
FBG(mmol/L) | 7.08(5.97, 9.23) | 6.46(5.54, 8.14) | 7.50(5.70, 10.16)# |
HbA1c(%) | 7.30(6.70, 8.00) | 7.30(6.45, 8.50) | 7.40(6.53, 8.50) |
BUN(mmol/L) | 5.90(5.05, 7.10) | 6.30(5.00, 7.35) | 6.60(5.30, 8.10) |
Cr(μmol/L) | 59.00(51.00, 68.00) | 67.00(58.00, 79.00)* | 69.00(57.00, 86.00)* |
UA(μmol/L) | 316.50(275.00, 376.00) | 335.00(300.50, 398.50) | 349.00(297.50, 414.00)* |
CysC(mg/L) | 0.89(0.81, 1.01) | 0.94(0.86, 1.04) | 0.99(0.93, 1.14)*# |
NLR | 1.73(1.34, 2.38) | 1.81(1.48, 2.72) | 2.70(2.12, 3.72)*# |
PLR | 103.21(83.14, 124.78) | 111.22(88.52, 144.68) | 136.14(109.18, 168.27)*# |
MLR | 0.19(0.14, 0.24) | 0.20(0.16, 0.29) | 0.27(0.22, 0.34)*# |
变量 | B值 | SE | Wald χ2值 | 95% | |||
---|---|---|---|---|---|---|---|
下限 | 上限 | ||||||
性别 | 0.780 | 0.260 | 9.019 | 0.003 | 2.181 | 1.311 | 3.629 |
年龄 | 0.033 | 0.014 | 5.963 | 0.015 | 1.034 | 1.007 | 1.062 |
DBP | -0.023 | 0.009 | 6.768 | 0.009 | 0.977 | 0.961 | 0.994 |
BMI | 0.133 | 0.049 | 7.402 | 0.007 | 1.142 | 1.038 | 1.257 |
TC | 0.223 | 0.331 | 0.454 | 0.501 | 1.250 | 0.653 | 2.392 |
LDL-C | 0.194 | 0.426 | 0.207 | 0.650 | 1.214 | 0.526 | 2.798 |
LDL-C/HDL-C | -0.096 | 0.163 | 0.345 | 0.557 | 0.909 | 0.660 | 1.251 |
UA | -0.001 | 0.001 | 0.170 | 0.680 | 0.999 | 0.997 | 1.002 |
Cr | 0.017 | 0.006 | 7.037 | 0.008 | 1.017 | 1.004 | 1.029 |
NLR | 0.286 | 0.136 | 4.402 | 0.036 | 1.331 | 1.019 | 1.739 |
PLR | 0.013 | 0.004 | 12.057 | 0.001 | 1.013 | 1.006 | 1.020 |
MLR | -0.809 | 1.527 | 0.265 | 0.001 | 0.445 | 0.020 | 9.705 |
Tab. 3 Ordered Logistic regression analysis of factors affecting the severity of coronary artery disease in patients with T2DM complicated with CHD
变量 | B值 | SE | Wald χ2值 | 95% | |||
---|---|---|---|---|---|---|---|
下限 | 上限 | ||||||
性别 | 0.780 | 0.260 | 9.019 | 0.003 | 2.181 | 1.311 | 3.629 |
年龄 | 0.033 | 0.014 | 5.963 | 0.015 | 1.034 | 1.007 | 1.062 |
DBP | -0.023 | 0.009 | 6.768 | 0.009 | 0.977 | 0.961 | 0.994 |
BMI | 0.133 | 0.049 | 7.402 | 0.007 | 1.142 | 1.038 | 1.257 |
TC | 0.223 | 0.331 | 0.454 | 0.501 | 1.250 | 0.653 | 2.392 |
LDL-C | 0.194 | 0.426 | 0.207 | 0.650 | 1.214 | 0.526 | 2.798 |
LDL-C/HDL-C | -0.096 | 0.163 | 0.345 | 0.557 | 0.909 | 0.660 | 1.251 |
UA | -0.001 | 0.001 | 0.170 | 0.680 | 0.999 | 0.997 | 1.002 |
Cr | 0.017 | 0.006 | 7.037 | 0.008 | 1.017 | 1.004 | 1.029 |
NLR | 0.286 | 0.136 | 4.402 | 0.036 | 1.331 | 1.019 | 1.739 |
PLR | 0.013 | 0.004 | 12.057 | 0.001 | 1.013 | 1.006 | 1.020 |
MLR | -0.809 | 1.527 | 0.265 | 0.001 | 0.445 | 0.020 | 9.705 |
[1] |
Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III)[J]. JAMA, 2001, 285: 2486-2497.
doi: 10.1001/jama.285.19.2486 URL |
[2] |
Tao LC, Xu JN, Wang TT, et al. Triglyceride-glucose index as a marker in cardiovascular diseases: Landscape and limitations[J]. Cardiovasc Diabetol, 2022, 21(1):68.
doi: 10.1186/s12933-022-01511-x |
[3] |
Gohari S, Reshadmanesh T, Khodabandehloo H, et al. The effect of empagliflozin on markers of inflammation in patients with concomitant type 2 diabetes mellitus and coronary artery disease: The EMPA-CARD randomized controlled trial[J]. Diabetol Metab Syndr, 2022, 14(1):170.
doi: 10.1186/s13098-022-00951-5 pmid: 36397128 |
[4] | Mertoglu C, Gunay M. Neutrophil-lymphocyte ratio and platelet-lymphocyte ratio as useful predictive markers of prediabetes and diabetes mellitus[J]. Diabetes Metab Syndr, 2017, 11:S127-S131. |
[5] | 郭倩云, 冯逊逊, 杨佳奇, 等. 老年2型糖尿病中性粒细胞与淋巴细胞比值与冠心病相关性的研究[J]. 心肺血管病杂志, 2022, 41(6):597-601. |
[6] |
Qiu Z, Jiang Y, Jiang X, et al. Relationship between platelet to lymphocyte ratio and stable coronary artery disease: Meta-analysis of observational studies[J]. Angiology, 2020, 71(10):909-915.
doi: 10.1177/0003319720943810 URL |
[7] | 郭姣姣, 龚开政. 中性粒细胞/淋巴细胞比值、血小板/淋巴细胞比值与2型糖尿病合并冠心病患者动脉粥样硬化程度的相关性[J]. 中华临床医师杂志(电子版), 2021, 15(3):171-176. |
[8] |
Qiao S, Gao W, Guo S. Neutrophil-lymphocyte ratio (NLR) for predicting clinical outcomes in patients with coronary artery disease and type 2 diabetes mellitus: A propensity score matching analysis[J]. Ther Clin Risk Manag, 2020, 16:437-443.
doi: 10.2147/TCRM.S244623 URL |
[9] | Urbanowicz T, Olasińska-Wi'sniewska A, Michalak M, et al. The prognostic significance of neutrophil to lymphocyte ratio (NLR), monocyte to lymphocyte ratio (MLR) and platelet to lymphocyte ratio (PLR) on long-term survival in off-pump coronary artery bypass grafting (OPCAB) procedures[J]. Biology (Basel), 2021, 11(1):34. |
[10] | 冯浠镰, 张伟, 杨柳柳. 单核细胞与淋巴细胞比值对重症患者病死率的预测意义[J]. 中国呼吸与危重监护杂志, 2022, 21(2):96-101. |
[11] |
Neeland IJ, Patel RS, Eshtehardi P, et al. Coronary angiographic scoring systems: An evaluation of their equivalence and validity[J]. Am Heart J, 2012, 164(4):547-552.
doi: 10.1016/j.ahj.2012.07.007 pmid: 23067913 |
[12] |
Rampidis GP, Benetos G, Benz DC, et al. A guide for gensini score calculation[J]. Atherosclerosis, 2019, 287:181-183.
doi: S0021-9150(19)30417-4 pmid: 31104809 |
[13] |
Sun H, Saeedi P, Karuranga S, et al. IDF diabetes atlas: Global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045[J]. Diabetes Res Clin Pract, 2022, 183:109119.
doi: 10.1016/j.diabres.2021.109119 URL |
[14] |
Soehnlein O, Libby P. Targeting inflammation in atherosclerosisfrom experimental insights to the clinic[J]. Nat Rev Drug Discov, 2021, 20(8):589-610.
doi: 10.1038/s41573-021-00198-1 pmid: 33976384 |
[15] |
Gijsberts CM, Ellenbroek GHJM, Ten Berg MJ, et al. Effect of monocyte-to-lymphocyte ratio on heart failure characteristics and hospitalizations in a coronary angiography cohort[J]. Am J Cardiol, 2017, 120(6):911-916.
doi: S0002-9149(17)31028-7 pmid: 28779870 |
[16] |
Zhu Y, Xian X, Wang Z, et al. Research progress on the relationship between atherosclerosis and inflammation[J]. Biomolecules, 2018, 8(3):80.
doi: 10.3390/biom8030080 URL |
[17] |
Zahorec R. Neutrophil-to-lymphocyte ratio, past, present and future perspectives[J]. Bratisl Lek Listy, 2021, 122(7):474-488.
doi: 10.4149/BLL_2021_078 pmid: 34161115 |
[18] |
Xiang F, Chen R, Cao X, et al. Monocyte/lymphocyte ratio as a better predictor of cardiovascular and all-cause mortality in hemodialysis patients: A prospective cohort study[J]. Hemodial Int, 2018, 22(1):82-92.
doi: 10.1111/hdi.12549 pmid: 28403540 |
[19] | Li XT, Fang H, Li D, et al. Association of platelet to lymphocyte ratio with in-hospital major adverse cardiovascular events and the severity of coronary artery disease assessed by the Gensini score in patients with acute myocardial infarction[J]. Chin Med J (Engl), 2020, 133(4):415-423. |
[20] |
He J, Bian X, Song C, et al. High neutrophil to lymphocyte ratio with type 2 diabetes mellitus predicts poor prognosis in patients undergoing percutaneous coronary intervention: A large-scale cohort study[J]. Cardiovasc Diabetol, 2022, 21(1):156.
doi: 10.1186/s12933-022-01583-9 pmid: 35964050 |
[21] |
Hudzik B, Szkodzinski J, Gorol J, et al. Platelet-to-lymphocyte ratio is a marker of poor prognosis in patients with diabetes mellitus and ST-elevation myocardial infarction[J]. Biomark Med, 2015, 9(3):199-207.
doi: 10.2217/bmm.14.100 pmid: 25731207 |
[22] |
Ji H, Li Y, Fan Z, et al. Monocyte/lymphocyte ratio predicts the severity of coronary artery disease: A syntax score assessment[J]. BMC Cardiovasc Disord, 2017, 17(1):90.
doi: 10.1186/s12872-017-0507-4 URL |
[23] | 刘逸翔, 范文俊, 丁振江, 等. WMR、MLR及两者联合对冠心病及冠状动脉病变严重程度的诊断价值[J]. 天津医药, 2022, 50(8):859-863. |
[24] | 马丽, 黄从新. 单核细胞/淋巴细胞比率与冠状动脉病变程度相关性的临床研究[J]. 心血管病学进展, 2020, 41(5):542-546. |
[25] | Khurana R, Yadav A, Buxi TBS, et al. Correlation of epicardial fat quantification with severity of coronary artery disease: A study in Indian population[J]. Indian Heart J, 2018, 70 Suppl 3(Suppl 3):S140-S145. |
[26] | 丰庆春, 谭茗月, 李安莹. 冠状动脉粥样硬化病人血脂、尿素氮、血肌酐与冠脉病变的对比分析[J]. 医学临床研究, 2005, 22(5):647-648. |
[27] |
Bagheri B, Radmard N, Faghani-Makrani A, et al. Serum creatinine and occurrence and severity of coronary artery disease[J]. Med Arch, 2019, 73(3):154-156.
doi: 10.5455/medarh.2019.73.154-156 pmid: 31404126 |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||